Company Overview
Snapshot
Founded in February 2018 by Eli Ben Simon, Tzvika Barkai, and Yehuda Yavets-Chen, Picodya Technologies operates with 11–50 employees. The company has raised a total of $51.4 million across 10 funding rounds. In January 2024, Picodya received a grant, highlighting ongoing support for its diagnostic platform.
Business overview
Picodya Technologies is a Health Tech & Life Sciences company focused on redefining diagnostics through its B-Matrix microfluidic lab-on-a-chip platform. This technology enables simultaneous hybrid testing for both molecular and immunoassays with multiplexed syndromic panels across various sample types. The platform's innovative multi-use consumables reduce costs, while minimal sample volume offers a less invasive patient experience. Picodya's modular design supports diverse clinical settings, from large hospital laboratories and urgent care facilities to physician offices, airports, pharmacies, and home care, operating within the Digital Healthcare, Medical Decision Support, Digital Medical Diagnostics, Medical Devices, and Diagnostics Devices sectors.
Strategic signal
In January 2024, Picodya Technologies announced the adoption of its B-Matrix multiplexed point-of-care testing systems by government laboratories across the US, as part of the National Institute of Health's (NIH) PREMISE initiative. This strategic partnership with the NIH, specifically the National Institute of Allergy and Infectious Diseases (NIAID), aims to establish a backlog of immunobiological countermeasures for future pandemic preparedness. This adoption signals significant validation of Picodya's technology and its potential for broad market expansion and critical public health infrastructure, positioning the company as a key player in global health security.
Log in to access full profile ›Company Intelligence Q&A
- What is Picodya Technologies' core product?
- Picodya Technologies' core product is the B-Matrix, a microfluidic lab-on-a-chip platform designed for In Vitro Diagnostics (IVD). It supports simultaneous hybrid testing for molecular and immunoassays with multiplexed syndromic panels.
- What significant partnership did Picodya Technologies announce in January 2024?
- In January 2024, Picodya Technologies announced that its B-Matrix multiplexed point-of-care testing systems are being implemented in government laboratories across the US as part of the National Institute of Health (NIH) PREMISE initiative. This partnership aims to establish immunobiological countermeasures for pandemic preparedness.
- When was Picodya Technologies founded and by whom?
- Picodya Technologies was founded in February 2018 by co-founders Eli Ben Simon, Tzvika Barkai, and Yehuda Yavets-Chen.
- What was a key development for Picodya Technologies in February 2021?
- In February 2021, Picodya Technologies completed a $10 million fundraising round led by SIBF (.
- What is the total capital raised by Picodya Technologies?
- Picodya Technologies has raised a total of $51.4 million across 10 funding rounds.